Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cann Group Ltd. ( (AU:CAN) ) has shared an announcement.
Cann Group Limited has secured an $836,469 funding advance from Radium Capital, which provides early access to its expected R&D Tax Incentive for FY2025. This advance will support the company’s strategy of supplying the medicinal cannabis market with unique products, including those sold under its Botanitech brand in collaboration with Chemist Warehouse outlets. The advance, under a loan agreement with a 15% annual interest rate, will be repaid upon receipt of the R&D Refund or by 31 October 2025. This move is expected to bolster Cann Group’s operations and strengthen its market positioning in the medicinal cannabis industry.
More about Cann Group Ltd.
Cann Group Limited is a company focused on enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. With research facilities and corporate headquarters in Melbourne, the company operates a large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group offers a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and globally. It also owns Satipharm and its patent-protected capsule technology.
YTD Price Performance: 63.64%
Average Trading Volume: 300
Technical Sentiment Signal: Buy
Current Market Cap: $6.18M
Find detailed analytics on CAN stock on TipRanks’ Stock Analysis page.